T. Rowe Price Associates
LFCR icon

T. Rowe Price Associates’s Lifecore Biomedical LFCR Stock Holding History

T. Rowe Price Associates’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66K Buy
17,680
+1,034
+6% +$7.14K ﹤0.01% 3048
2025
Q4 		$137K Buy
16,646
+2,826
+20% +$20.9K ﹤0.01% 2902
2025
Q3 		$102K Buy
13,820
+700
+5% +$5.3K ﹤0.01% 2920
2025
Q2 		$107K Buy
13,120
+2,321
+21% +$15.6K ﹤0.01% 2879
2025
Q1 		$77K Buy
+10,799
New +$67.1K ﹤0.01% 2873

Other funds holding LFCR

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates's LFCR Position: Q1 2026 in Review

T. Rowe Price Associates increased its Lifecore Biomedical (LFCR) stake by 6.2% in Q1 2026, buying an estimated $7.14K and bringing the position to 17,680 shares worth $66K. The position accounts for ﹤0.01% of the portfolio, ranked #3048.

T. Rowe Price Associates first reported a position in LFCR in Q1 2025 and has held it in 5 quarters since. The position peaked at $137K in Q4 2025. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

  • T. Rowe Price Associates held 17,680 shares of Lifecore Biomedical worth $66K as of Q1 2026.
  • T. Rowe Price Associates bought 1,034 Lifecore Biomedical shares in Q1 2026, an estimated $7.14K.
  • Lifecore Biomedical made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3048 holding.
  • T. Rowe Price Associates first reported a position in Lifecore Biomedical in Q1 2025 and has held it in 5 quarters since.
  • T. Rowe Price Associates's Lifecore Biomedical position peaked at $137K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.